AKUMS

What Akums Drugs promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 20 tracked 4 delivered 5 missed 11 open
  • API Segment Profitability missed said Q3 FY25 Promised: Breakeven in 1 to 2 years Q1 FY27: Original promise remains missed. Management has issued a new, more specific target to be monthly EBITDA positive by Feb-Mar 2027.
  • Zambia JV Supply Revenue delayed said Q2 FY26 Promised: US$50 million over the next two years Q1 FY27: Timeline further clarified to 'likely be in Q3 and maybe some parts in Q4' of FY27, a slight pushback from 'end of Q2 FY27'.
  • EU CDMO Contract Annual Revenue on track said Q4 FY25 Promised: INR 300-350 crores steady state FY28 onwards Q1 FY27: Management confirmed they will 'kickstart our European business' within the next financial year (FY28), keeping the project on its stated timeline.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 20 tracked commitments for Akums Drugs — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens